system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: BACKGROUND, RESULTS. Meshes: Adolescent, Adult, Aged, Aged, 80 and over, Aging, Cell Line, Tumor, Child, Child, Preschool, ERG1 Potassium Channel, Ether-A-Go-Go Potassium Channels, Female, Gene Expression Regulation, Leukemic, Humans, Infant, Leukemia, Myeloid, Acute, Male, Middle Aged, Prognosis, Survival Analysis, Treatment Outcome, Young Adult.
user
Is the potassium channel Ether à go-go a novel prognostic factor with functional relevance in acute myeloid leukemia? Context: The voltage-gated potassium channel hEag1 (KV10.1) has been related to cancer biology. The physiological expression of the human channel is restricted to the brain but it is frequently and abundantly expressed in many solid tumors, thereby making it a promising target for a specific diagnosis and therapy. Because chronic lymphatic leukemia has been described not to express hEag1, it has been assumed that the channel is not expressed in hematopoietic neoplasms in general. Here we show that this assumption is not correct, because the channel is up-regulated in myelodysplastic syndromes, chronic myeloid leukemia and almost half of the tested acute myeloid leukemias in a subtype-dependent fashion. Most interestingly, channel expression strongly correlated with increasing age, higher relapse rates and a significantly shorter overall survival. Multivariate Cox regression analysis revealed hEag1 expression levels in AML as an independent predictive factor for reduced disease-free and overall survival; such an association had not been reported before. As a functional correlate, specific hEag1 blockade inhibited the proliferation and migration of several AML cell lines and primary cultured AML cells in vitro.
assistant
Our observations implicate hEag1 as novel target for diagnostic, prognostic and/or therapeutic approaches in AML. Final Decision: yes